531592 — Genpharmasec Income Statement
0.000.00%
- IN₹1.10bn
- IN₹1.10bn
- IN₹304.06m
Annual income statement for Genpharmasec, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 165 | 213 | 273 | 255 | 304 |
Cost of Revenue | |||||
Gross Profit | 12.6 | 21.1 | 7.55 | 21.2 | 61.7 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 159 | 201 | 279 | 253 | 304 |
Operating Profit | 6.48 | 11.8 | -5.36 | 2.37 | 0.039 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 12.1 | 15.1 | -4.43 | 2.82 | 2.51 |
Provision for Income Taxes | |||||
Net Income After Taxes | 10.1 | 12.6 | -2.09 | 11.2 | -1.69 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 10.1 | 12.6 | -2.09 | 11.2 | -1.26 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 10.1 | 12.6 | -2.09 | 11.2 | -1.26 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.012 | 0.027 | -0.005 | 0.024 | -0.004 |